A person walks past a sign that reads, ‘The vaccine is our best chance against COVID-19’ on the Upper West Side amid the coronavirus pandemic on March 30, 2021 in New York City.
Noam Galai | Getty Images
Johnson & Johnson has privately asked Pvizer and Moderna’s competitors against Covid-19 to participate in a study examining the potential risk of blood clots, but the businesses have declined, The Wall Street Journal reported Friday, citing people who familiar with the matter.
Pfizer and Moderna executives said their vaccines look safe and they do not see the need to duplicate the efforts of regulators and companies, according to the Journal report.
Only AstraZeneca, whose vaccine has also raised concerns from regulators about blood clots, agreed to take part in the effort, the Journal said.
CNBC released the four companies for comment.
The Food and Drug Administration and the Centers for Disease Control and Prevention on Tuesday advised the states to temporarily suspend the use of J & J’s vaccine ‘out of abundance caution’ after six women developed a rare but potentially life-threatening blood clotting disorder. one is dead and one in critical condition.
U.S. health officials told reporters the women developed the condition known as cerebral venous sinus thrombosis, or CVST, within two weeks of receiving the shot. CVST is a rare form of stroke that occurs when a blood clot forms in the venous sinuses of the brain. It can eventually leak blood into the brain tissue and cause bleeding.
A CDC panel on Wednesday decided to postpone a decision on the use of J & J’s vaccine while officials investigated the cases.
Read the full Wall Street Journal report here.